Skip to content

Effect of L arginine on epilepsy

Evaluation of the effect of L-arginine on patiant with refractory epilepsy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201603078436N3
Enrollment
42
Registered
2016-04-29
Start date
2016-04-02
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy.

Interventions

Intervention 1: L-arginine 2 size of daily need every day for three months. Intervention 2: placebo(starch) 3-6 tablets every day for three months.
Treatment - Drugs
L-arginine 2 size of daily need every day for three months
placebo(starch) 3-6 tablets every day for three months

Sponsors

Neurology Research Center Kerman University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: inclusion : patients with epilepsy who have not responses to combination therapy(at least 2 attack per month) by antiepileptic drugs (at least 2 drugs); Exclusion: any disorders except epilepsy; Neurologic disorder except epilepsy; Pregnancy; hypersensitivity or adverse events to L-rrginine

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Number of epileptic attacks. Timepoint: Duration of every attack in one month. Method of measurement: number.;Severity of attacks. Timepoint: duration every attack. Method of measurement: number.

Secondary

MeasureTime frame
Non-tolerance. Timepoint: 3 months. Method of measurement: report.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdi Ansari

Research manager of Kerman university of medical sciences

mansari@yahoo.co+98 34 3226 3815

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026